ＥＧＦＲ抑制劑及其製備和應用

• 收藏
• 分享

专利权人:

SHANGHAI HANSOH BIOMEDICAL CO., LTD.;JIANGSU HANSOH PHARMACEUTICAL CO., LTD.

发明人:

YU, HONGPING,喻红平,喻紅平,WEI, MINGSONG,危明松,CUI, YUANYUAN,崔媛媛,SUN, XINGYI,孙兴义,孫興義,TONG, ZHAOLONG,仝朝龙,仝朝龍,SUN, GUANGJUN,孙广俊,孫廣俊,TAN, SONGLIANG,谭松良,譚松良,MA, JIANBIN,马建斌,馬建斌,GAO, PENG,高鹏,高鵬,LIAO, JIANC

申请号：

TW104133007

公开号：

TW201613875A

申请日:

2015.10.07

申请国别(地区):

TW

年份:

2016

代理人:

摘要：

The present invention discloses EGFR inhibitors, their preparation and the use thereof. Specially, the present invention relates to a formula (I), the derivates of 4-substituted-2-(N-(5-allyl amide) phenyl) amino) pyrimidine. The series of compounds with activity of inhibiting L858R EGFR mutant, T790M EGFR mutants and exon 19 deletion mutants can be used as treating diseases mediated by EGFR mutants alone or in part. For example, it can be widely used as prevention and treatment cancer, especially non-small cell lung cancer and is expected to develop a new generation EGFR inhibitor.本發明公開了EGFR抑制劑及其製備和應用。具體地，本發明涉及一種式(I)化合物4-取代-2-(N-(5-取代烯丙醯胺基)苯基)胺基)嘧啶衍生物。該系列化合物具有抑制L858R EGFR突變體、T790M EGFR突變體和外顯子19缺失啟動突變體的活性，可以用來治療單獨或部分地由EGFR突變體活性介導疾病，例如在預防與治療癌症尤其是非小細胞肺癌藥物中的具有廣泛應用，有望開發成新一代EGFR抑制劑。

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/